Bionoid Pharma's 2024 Audit: A Milestone in Transparency and Growth

In the fast-paced world of biotech and pharma, transparency and financial governance are the cornerstones of investor confidence. Bionoid Pharma Inc. (OTC PINK:BINP) has taken a significant step forward in this regard with the successful completion of its 2024 financial audit by Aloba Awomolo & Partners LLP. This milestone not only underscores the company's commitment to robust financial practices but also positions it for future growth and market visibility.

The completion of the 2024 audit is a critical achievement for Bionoid Pharma. As Wayne Cockburn, CEO of Bionoid Pharma, stated, "Completing our 2024 audit puts us in a strong position as we now shift our focus toward the next phase of our corporate growth strategy - including the work required to advance our application to uplist to a more senior stock exchange." This move is aimed at enhancing market presence and shareholder value, reflecting the company's dedication to providing investors with increased visibility and liquidity.

The audit, conducted by Aloba Awomolo & Partners LLP, a PCAOB-registered accounting firm, ensures that Bionoid's financial statements are accurate and compliant with regulatory standards. This transparency is essential for building trust with investors and stakeholders. The audited financial statements will be filed on OTC Markets, providing investors with access to detailed and verified financial information.

Bionoid Pharma's strategic focus on AI-driven growth initiatives and acquisitions provides several key advantages that can significantly contribute to its long-term financial performance and market valuation. The company's proprietary AI Maverick platform is designed to support a wide range of applications, from intelligent customer interaction tools to dynamic communication and data-driven engagement systems. This AI-powered platform enhances operational efficiency by automating processes and improving data analysis, which can lead to cost savings and increased productivity.

The company's five-year roadmap includes acquiring revenue-generating businesses, which can provide immediate revenue streams and expand its market presence. For example, Bionoid has signed a Binding Letter of Intent (LOI) with Vitawin Supplements Ltd. to acquire its main e-commerce platform, which can significantly boost Bionoid's e-commerce presence and revenue. Additionally, the company has reported over $100,000 in revenue following the signing of a Binding LOI with Your Supplement Supply Store Ltd., demonstrating the potential financial benefits of these acquisitions.

Bionoid Pharma's application to uplist to the OTCQB Venture Market is a strategic move aimed at enhancing market visibility and liquidity. This uplisting can attract more investors and provide increased transparency, which can lead to a higher market valuation. As stated in the press release, "this audit represents a critical step toward achieving a more senior listing and reflects our dedication to providing investors with increased visibility and liquidity."

In summary, the completion of the 2024 financial audit by Aloba Awomolo & Partners LLP strengthens Bionoid Pharma's market position by enhancing financial transparency, supporting its uplisting application, boosting investor confidence, and positioning the company for future growth. The company's strategic focus on AI-driven growth initiatives and acquisitions provides key advantages such as enhanced operational efficiency, improved user experience, increased market visibility, and long-term value creation. These factors can contribute to Bionoid Pharma's long-term financial performance and market valuation by driving revenue growth, improving profitability, and attracting more investors.